Denali Stock Analysis

DNLI Stock  USD 21.39  0.60  2.73%   
The main objective of Denali Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Denali Therapeutics is worth, separate from its market price. There are two main types of Denali Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Denali Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Denali Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Denali Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Denali Therapeutics is usually not traded on Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Veterans Day ( substitute day ), Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday. Denali Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Denali Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

Denali Stock Analysis Notes

About 15.0% of the company shares are held by company insiders. The book value of Denali Therapeutics was currently reported as 8.64. The company recorded a loss per share of 1.07. Denali Therapeutics had not issued any dividends in recent years. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To learn more about Denali Therapeutics call Ryan Watts at 650 866 8548 or check out

Denali Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Denali Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Denali Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Denali Therapeutics generated a negative expected return over the last 90 days
Denali Therapeutics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 108.46 M. Net Loss for the year was (325.99 M) with loss before overhead, payroll, taxes, and interest of (250.27 M).
Denali Therapeutics currently holds about 1.07 B in cash with (244.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66.
Over 80.0% of the company shares are held by institutions such as insurance companies
Latest headline from Optimistic Outlook for Axsome Therapeutics Analysts Predict ... - Best Stocks

Denali Therapeutics Upcoming and Recent Events

Earnings reports are used by Denali Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Denali Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
2nd of November 2023
Upcoming Quarterly Report
26th of February 2024
Next Financial Report
30th of September 2023
Next Fiscal Quarter End
26th of February 2024
Next Fiscal Year End
30th of June 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Denali Largest EPS Surprises

Earnings surprises can significantly impact Denali Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Denali Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Denali Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Denali Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Denali Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
21st of August 2023
Entry into a Material Definitive Agreement
8th of August 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
20th of June 2023
Financial Statements and Exhibits. Other Events
5th of June 2023
Other Events
2nd of June 2023
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders
8th of May 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
30th of March 2023
Unclassified Corporate Event
27th of February 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition

Denali Therapeutics Thematic Classifications

In addition to having Denali Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Denali Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.2 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Denali Therapeutics's market, we take the total number of its shares issued and multiply it by Denali Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Denali Profitablity

Denali Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Denali Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Denali Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Denali Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Denali Therapeutics' profitability requires more research than a typical breakdown of Denali Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.48.
Last ReportedProjected for 2023
Return on Investment(33.99)(36.68)
Return on Average Assets(0.25)(0.27)
Return on Average Equity(0.36)(0.37)
Return on Invested Capital(0.37)(0.40)
Return on Sales(3.00)(3.24)

Management Efficiency

Denali Therapeutics has return on total asset (ROA) of (0.0785) % which means that it has lost $0.0785 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.124) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -36.68. The current Return on Average Assets is estimated to decrease to -0.27. Denali Therapeutics Net Current Assets as percentage of Total Assets are decreasing as compared to previous years. The last year's value of Net Current Assets as percentage of Total Assets was reported at 69.06. The current Asset Turnover is estimated to increase to 0.10, while Total Assets are projected to decrease to under 1.2 B.
Last ReportedProjected for 2023
Book Value per Share 8.30  7.85 
Enterprise Value over EBIT(11.00)(11.29)
Enterprise Value over EBITDA(11.79)(12.10)
Price to Book Value 3.62  4.69 
Tangible Assets Book Value per Share 11.63  13.38 
Enterprise Value3.7 B4.2 B
Tangible Asset Value1.5 B1.2 B
The analysis of Denali Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Denali Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Denali Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Short Long Term Debt Total
60.4 M
Income Tax Expense
21 K
Interest Expense
14.8 M
Total Operating Expenses
449.2 M
Other Operating Expenses
449.2 M

Technical Drivers

As of the 26th of September, Denali Therapeutics shows the Standard Deviation of 1.95, mean deviation of 1.52, and Variance of 3.81. Denali Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Denali Therapeutics, which can be compared to its rivals. Please confirm Denali Therapeutics variance and value at risk to decide if Denali Therapeutics is priced favorably, providing market reflects its regular price of 21.39 per share. Given that Denali Therapeutics has information ratio of (0.22), we urge you to verify Denali Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Denali Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Denali Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Denali Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Denali Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Denali Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Denali Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Denali Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Denali Therapeutics Technical and Predictive Indicators

Denali Therapeutics Forecast Models

Denali Therapeutics' time-series forecasting models are one of many Denali Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Denali Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Denali Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Denali Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Denali shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Denali Therapeutics. By using and applying Denali Stock analysis, traders can create a robust methodology for identifying Denali entry and exit points for their positions.
Last ReportedProjected for 2023
Operating Margin 16.82  18.15 
EBITDA Margin(2.91)(3.14)
Gross Margin 0.90  0.89 
Profit Margin(3.01)(3.25)

Current Denali Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Denali analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Denali analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Denali Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Denali analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Denali stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Denali Therapeutics, talking to its executives and customers, or listening to Denali conference calls.
Denali Analyst Advice Details

Denali Stock Analysis Indicators

Denali Therapeutics stock analysis indicators help investors evaluate how Denali Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Denali Therapeutics shares will generate the highest return on investment. By understating and applying Denali Therapeutics stock analysis, traders can identify Denali Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow295 M
Common Stock Shares Outstanding125.5 M
Total Stockholder EquityB
Tax Provision21 K
Property Plant And Equipment Net74.5 M
Cash And Short Term Investments1.3 B
Cash218 M
Accounts Payable2.8 M
Net Debt-157.7 M
50 Day M A26.79
Total Current Liabilities363.9 M
Other Operating Expenses449.2 M
Non Current Assets Total87.9 M
Non Currrent Assets Other13.4 M
Stock Based Compensation99.8 M
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.